Your browser doesn't support javascript.
loading
Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells.
Grinshtein, Natalie; Rioseco, Constanza C; Marcellus, Richard; Uehling, David; Aman, Ahmed; Lun, Xueqing; Muto, Osamu; Podmore, Lauren; Lever, Jake; Shen, Yaoqing; Blough, Michael D; Cairncross, Greg J; Robbins, Stephen M; Jones, Steven J; Marra, Marco A; Al-Awar, Rima; Senger, Donna L; Kaplan, David R.
Afiliação
  • Grinshtein N; Program in Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, Canada.
  • Rioseco CC; Program in Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, Canada.
  • Marcellus R; Drug Discovery Group, Ontario Institute for Cancer Research, Toronto, Canada.
  • Uehling D; Drug Discovery Group, Ontario Institute for Cancer Research, Toronto, Canada.
  • Aman A; Drug Discovery Group, Ontario Institute for Cancer Research, Toronto, Canada.
  • Lun X; Arnie Charbonneau Cancer Institute, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Muto O; Program in Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, Canada.
  • Podmore L; Program in Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, Canada.
  • Lever J; Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada.
  • Shen Y; Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada.
  • Blough MD; Arnie Charbonneau Cancer Institute, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Cairncross GJ; Arnie Charbonneau Cancer Institute, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Robbins SM; Arnie Charbonneau Cancer Institute, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Jones SJ; Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada.
  • Marra MA; Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
  • Al-Awar R; Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia.
  • Senger DL; Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada.
  • Kaplan DR; Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
Oncotarget ; 7(37): 59360-59376, 2016 09 13.
Article em En | MEDLINE | ID: mdl-27449082
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piridonas / Neoplasias Encefálicas / Ensaios de Seleção de Medicamentos Antitumorais / Glioblastoma / Inibidores de Histona Desacetilases / Proteína Potenciadora do Homólogo 2 de Zeste / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Oncotarget Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Canadá País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piridonas / Neoplasias Encefálicas / Ensaios de Seleção de Medicamentos Antitumorais / Glioblastoma / Inibidores de Histona Desacetilases / Proteína Potenciadora do Homólogo 2 de Zeste / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Oncotarget Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Canadá País de publicação: Estados Unidos